Prediction of response to cancer chemotherapy using immunohistochemical staining

DOI IR (HANDLE) Web Site 9 References Open Access
  • Kamoshida Shingo
    Department of Medical Biophysics, Kobe University Graduate School of Health Sciences

Bibliographic Information

Other Title
  • 免疫組織化学染色によるがん化学療法の感受性予測

Search this article

Description

<p>Here, we review the utility of immunohistochemical (IHC) staining as a diagnostic assay in cancers. IHC staining for hormone receptors is used to select patients for hormonal therapy in breast cancers. IHC staining and fluorescent in situ hybridization (FISH) are well-established assays for overexpression of human epidermal growth factor receptor 2 (HER2) protein and amplification of the HER2 gene, respectively; positive results indicate that targeted therapy with trastuzumab, the anti-HER2 antibody, is appropriate. Similarly, the anaplastic lymphoma kinase (ALK) inhibitors, crizotinib and alectinib, can treat non-small cell lung cancers with ALK fusion genes, which are found through diagnostic assays that include IHC staining and FISH; and imatinib is effective for KIT-expressing gastrointestinal stromal tumors. IHC confirmation of target protein expression is also necessary before using targeted agents in hematologic malignancies: CD20 for rituximab, CD30 for brentuximab vedotin, and CC chemokine receptor-4 for mogamurizumab. IHC staining for programmed death-ligand 1 is used to identify non-small cell lung cancer patients who can respond to pembrolizumab, which targets programmed death-1. This review also discusses possible prediction of response to cytotoxic agents through IHC staining for solute carrier transporters, and the differences between IHC staining and western blotting.</p>

Journal

References(9)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top